Home » Topics » Disease categories and therapies » Urology

Urology
RSS

FibroGen and Taisho to collaborate on kidney fibrosis research

Sep. 8, 1999

No Comments

YM-31758: a potent and selective inhibitor of human prostatic 5alpha-reductase

Sep. 6, 1999

No Comments

New treatment for urinary incontinence in the Recordati pipeline

Aug. 31, 1999

No Comments

Long-term continuation rate good for Alza's overactive bladder therapy

Aug. 30, 1999

No Comments

Long-term tolterodine reduces incontinence, is well tolerated

Aug. 30, 1999

No Comments

Ferring's antidiuretic agent F-992 evaluated in healthy volunteers

Aug. 26, 1999

No Comments

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Aug. 23, 1999

No Comments

Sanofi-Synthelabo submits MAA for Ditropan XL in the U.K.

Aug. 16, 1999

No Comments

Leading BPH treatment to be copromoted by Abbott and Boehringer Ingelheim

Aug. 16, 1999

No Comments

NexMed reports results from multiple-use study of topical alprostadil cream

Aug. 16, 1999

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Urology
RSS

FibroGen and Taisho to collaborate on kidney fibrosis research

YM-31758: a potent and selective inhibitor of human prostatic 5alpha-reductase

New treatment for urinary incontinence in the Recordati pipeline

Long-term continuation rate good for Alza's overactive bladder therapy

Long-term tolterodine reduces incontinence, is well tolerated

Ferring's antidiuretic agent F-992 evaluated in healthy volunteers

ACS news: Wyeth-Ayerst investigates agents for urinary incontinence

Sanofi-Synthelabo submits MAA for Ditropan XL in the U.K.

Leading BPH treatment to be copromoted by Abbott and Boehringer Ingelheim

NexMed reports results from multiple-use study of topical alprostadil cream

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Urology RSS

Urology
RSS